Last reviewed · How we verify
NCT07017712: SeDiGCS
Sex Differences in Gastrointestinal Cancer Surgery
trial testing Complex esophageal surgery for carcinoma in Sex in 870,754 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | Medizinische Hochschule Brandenburg Theodor Fontane |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 870,754 |
| Start date | 1 January 2010 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
Drugs / interventions tested
- Complex esophageal surgery for carcinoma
- Rectum resection for carcinoma
- Colon resection for carcinoma
- Pancreatic resection for carcinoma
- Gastric resection for carcinoma
Conditions studied
- Sex — all drugs for Sex →
- Gastrointestinal Cancers — all drugs for Gastrointestinal Cancers →
- Surgical Resection — all drugs for Surgical Resection →
- Sex Differences — all drugs for Sex Differences →
Sponsor
Medizinische Hochschule Brandenburg Theodor Fontane
Who can join
18 and older, any sex, with Sex or Gastrointestinal Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate whether there are differences in surgical outcomes between male and female patients with gastrointestinal cancers (esophagus, colon, rectum, stomach, or pancreas). Previous research suggests that women may have worse outcomes after high-risk surgeries, such as heart or vascular procedures, but it is unclear if this applies to gastrointestinal cancer surgery. The study will analyze population based data from Germany to compare how often male and female patients died or died after the occurence of a surgical complication (failure to rescue) after surgery. The goal is to determine if biological sex influences surgical risks and recovery, which could help improve personalized care for cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07017712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medizinische Hochschule Brandenburg Theodor Fontane trials
Trials by the same sponsor.
- NCT06902337 — Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany · active not recruiting
- NCT07017153 — Patient Decision Aids for Hypertension: A Pilot Study · NA · completed
- NCT06575582 — Digital Navigators for Acceptance and Competence Development with Mental Health Apps · NA · recruiting
- NCT06631560 — Hepatitis E Virus Infection in Oncological Patients · NA · completed
- NCT03052283 — Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07017712 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medizinische Hochschule Brandenburg Theodor Fontane
- Last refreshed: 12 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07017712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing